Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Performance and Results of Operations
BIIB logo

Biogen's Q3 Revenues Rise 2.8% as Rare Diseases Surge Amid MS Declines

BIIB10-QFiling Date: 10/30/2025
Biogen Inc.
Description

What this story covers

Biogen's Q3 2025 revenues grew 2.8% to $2.53B, driven by rare disease launches like SKYCLARYS up 29.9%, offsetting MS generics. Net income rose 20.1% to $466.5M; cash at $3.96B supports pipeline deals in immunology and Alzheimer's. Restructuring yields efficiencies despite regulatory risks.

Story snapshot

CompanyBiogen Inc.
TickerBIIB
VariantStandard detailed
Duration17:13
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0000875045-25-000049

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in